Evaxion’s AI tech IDs cancer vaccine targets tied to longer progression-free survival in melanoma

 

• The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability

• Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients

• High-quality neoantigens, predicted by AI technology, were associated with longer progression-free survival

• Strong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients

• Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome

https://finance.yahoo.com/news/evaxion-ai-technology-identifies-cancer-210000739.html